ID   PEO1-CDDP
AC   CVCL_Y032
SY   PEO1CDDP; PEO1 cDDPr
DR   cancercelllines; CVCL_Y032
DR   CancerTools; 151784
DR   ECACC; 16012001
DR   Wikidata; Q54947163
DR   Ximbio; 151784
RX   PubMed=8824553;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Tyr1655Ter (c.4965C>G) (5193C>G); ClinVar=VCV000037936; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Unspecified (from parent cell line).
CC   Discontinued: ECACC; 16012001; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): ECACC=16012001
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 10
ST   D16S539: 9
ST   D18S51: 16,17
ST   D21S11: 32.2
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 13
ST   FGA: 20
ST   Penta D: 14
ST   Penta E: 11,12
ST   TH01: 9.3
ST   TPOX: 9,11
ST   vWA: 15,16
DI   NCIt; C36101; BRCA2 syndrome
DI   NCIt; C5228; Ovarian cystadenocarcinoma
DI   ORDO; Orphanet_145; Hereditary breast and ovarian cancer syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2686 ! PEO1
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 10-04-25; Version: 19
//
RX   PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#;
RA   Mullen, Peter
RA   Ritchie, Alison
RA   Langdon, Simon P.
RA   Miller, William R.
RT   "Effect of Matrigel on the tumorigenicity of human breast and ovarian
RT   carcinoma cell lines.";
RL   Int. J. Cancer 67:816-820(1996).
//